Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience
Ana Palanca, Falco van Nes, Felipe Pardo, et al.
Diabetes Care (2022) Vol. 45, Iss. 3, pp. 650-658
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S179-S218
Open Access | Times Cited: 178
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Matthew Anson, Sizheng Steven Zhao, Philip Austin, et al.
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1869-1881
Open Access | Times Cited: 48
Hyperglycemic Crises in Adults With Diabetes: A Consensus Report
Guillermo E. Umpierrez, Georgia M. Davis, Nuha A. ElSayed, et al.
Diabetes Care (2024) Vol. 47, Iss. 8, pp. 1257-1275
Open Access | Times Cited: 46
Hyperglycaemic crises in adults with diabetes: a consensus report
Guillermo E. Umpierrez, Georgia M. Davis, Nuha A. ElSayed, et al.
Diabetologia (2024) Vol. 67, Iss. 8, pp. 1455-1479
Open Access | Times Cited: 30
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S207-S238
Closed Access | Times Cited: 28
New advances in type 1 diabetes
Savitha Subramanian, Farah Khan, Irl B. Hirsch
BMJ (2024), pp. e075681-e075681
Open Access | Times Cited: 24
Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
Khary Edwards, Xilong Li, Ildiko Lingvay
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 108, Iss. 4, pp. 920-930
Closed Access | Times Cited: 55
The emergence of obesity in type 1 diabetes
Martin Tze Wah Kueh, Nicholas Chew, Ebaa Al‐Ozairi, et al.
International Journal of Obesity (2023) Vol. 48, Iss. 3, pp. 289-301
Open Access | Times Cited: 34
SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations
Pietro Maffei, Silvia Bettini, Luca Busetto, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 3579-3598
Open Access | Times Cited: 19
Insulin Resistance and CGM-Derived Parameters in People With Type 1 Diabetes: Are They Associated?
Isabel Clinck, Jonathan Mertens, Kristien Wouters, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 7
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes
Vikas S. Sridhar, Christine P. Limonte, Per‐Henrik Groop, et al.
Diabetologia (2023) Vol. 67, Iss. 1, pp. 3-18
Closed Access | Times Cited: 11
Overview on chronic complications of diabetes mellitus
Bogdan Vlacho, Joana Rossell-Rusiñol, Minerva Granado-Casas, et al.
Elsevier eBooks (2024), pp. 1-10
Closed Access | Times Cited: 4
Four-year use of SGLT2i as adjunctive therapy in adults with type 1 diabetes: a real-world experience
Marina Valenzano, Louis Massari, Paolo Abrate, et al.
Acta Diabetologica (2025)
Closed Access
Effect of sodium‐glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin‐treated diabetic dogs
Jessica R. Box, Mark A. Oyama, Ariel S. Mosenco, et al.
Journal of Veterinary Internal Medicine (2024) Vol. 38, Iss. 3, pp. 1353-1358
Open Access | Times Cited: 3
Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks
Ahmad Mamoun Rajab, Sam M. Pearson, Ramzi Ajjan
Diabetes Obesity and Metabolism (2025)
Open Access
Long-term effects of adding an SGLT-2 inhibitor to insulin therapy in patients with type 1 diabetes. An observational study and systematic review of real-world evidence
Alberto Maran, Federico Boscari, Carlo Fagarazzi, et al.
Journal of Endocrinological Investigation (2025)
Open Access
From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients
Theocharis Koufakis, Омар Мустафа, Ramzi Ajjan, et al.
Drugs (2022) Vol. 82, Iss. 9, pp. 949-955
Open Access | Times Cited: 16
Treating obesity in type 1 diabetes mellitus – review of efficacy and safety
Matthew Freeby, Kyrstin Lane
Current Opinion in Endocrinology Diabetes and Obesity (2023)
Closed Access | Times Cited: 9
Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes
Ebaa Al‐Ozairi, Mohammad Irshad, Etab Taghadom, et al.
Obesity (2023) Vol. 31, Iss. 3, pp. 716-723
Open Access | Times Cited: 8
Incretins beyond type 2 diabetes
Chantal Mathieu, Iraj Ahmadzai
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1809-1819
Closed Access | Times Cited: 8
Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study
Marı́a Durán-Martinez, Sharona Azriel, Viyey Doulatram‐Gamgaram, et al.
Diabetes & Metabolism (2023) Vol. 50, Iss. 1, pp. 101501-101501
Open Access | Times Cited: 8
Chronic treatment with SGLT-2 inhibitors is associated with ICU admission and disease severity in patients with diabetic ketoacidosis: a propensity score–matched cohort study
Fernando Sebastián-Valles, Maria Sara Tapia-Sanchiz, Víctor Navas-Moreno, et al.
Internal and Emergency Medicine (2024)
Closed Access | Times Cited: 3
Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes
Miodrag Janić, Matej Cankar, Jan Šmíd, et al.
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 13
Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
Carmen Tisch, Eleni Xourgia, Aristomenis K. Exadaktylos, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 660-675
Open Access | Times Cited: 2
New therapies towards a better glycemic control in youths with type 1 diabetes
Roque Cardona‐Hernandez, Klemen Dovč, Torben Biester, et al.
Pharmacological Research (2023) Vol. 195, pp. 106882-106882
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top